Vertex Reports Full-Year and Fourth-Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street closes lower as oil prices jump, indexes notch monthly gains
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
- Energy stocks rally as fresh U.S.-Iran attacks drive oil prices higher
- BofA turns S&P 500 signals from red to yellow: What to buy now
Vertex (VRTX) PT Raised to $285 at SunTrust
January 31, 2020 6:40 AM ESTSunTrust analyst Robyn Karnauskas raised the price target on Vertex (NASDAQ: VRTX) to $285.00 (from $235.00) while maintaining a Buy rating following results.
The analyst commented, "Recent approval of VRTX's drug TRIKAFTA and strong early launch metrics de-risk CF revenues for VRTX, in our... More
Vertex Pharma (VRTX) Tops Q4 EPS by 50c, Revenues Beat; Offers FY20 Revenue Guidance Above Consensus
January 30, 2020 4:04 PM ESTVertex Pharma (NASDAQ: VRTX) reported Q4 EPS of $1.70, $0.50 better than the analyst estimate of $1.20. Revenue for the quarter came in at $1.26 billion versus the consensus estimate of $1.01 billion.
"In 2019, our differentiated strategy of investing in serial scientific innovation to create transformative medicines... More
